Crossmark

HBV vaccination and PMTCT as elimination tools in the presence of HIV: insights from a clinical cohort and dynamic model

Crossref DOI link: https://doi.org/10.1186/s12916-019-1269-x

Published Online: 2019-02-21

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

McNaughton, Anna L.

Lourenço, José

Hattingh, Louise

Adland, Emily

Daniels, Samantha

Van Zyl, Anriette

Akiror, Connie S.

Wareing, Susan

Jeffery, Katie

Ansari, M. Azim

Klenerman, Paul

Goulder, Philip J. R.

Gupta, Sunetra

Jooste, Pieter

Matthews, Philippa C. https://orcid.org/0000-0002-4036-4269
Funding

Funding for this research was provided by:

Wellcome Trust (110110, 109965, 104748)

Rosetrees Trust (n/a)

European Research Council (268904-DIVERSITY)

National Institute for Health Research (n/a)
License Information

Text and Data Mining valid from 2019-02-21
More Information

Article History

Received: 24 September 2018

Accepted: 22 January 2019

First Online: 21 February 2019

Ethics approval and consent to participate

: Ethics approval was obtained from the Ethics Committee of the Faculty of Health Science, University of the Free State, Bloemfontein, South Africa (HIV Study Ref: ETOVS Nr 08/09 and COSAC Study Ref: ECUFS NR 80/2014), and from the Oxfordshire Research Ethics Committee A, ref 06/Q1604/12. Written consent for enrollment into the study was obtained from the child’s parent/guardian.

: Not applicable.

: PCM is an Associate Editor for BMC Infectious Diseases and undertakes consultancy work for Immunocore.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.